Use quotation marks("") to search for exact phrase or group of words
e.g. "breakbone fever"
Use "OR" to get either results
Placing "OR" in between your keywords gives you more results
e.g. dengue OR "breakbone fever"
Use "NOT" to exclude words
e.g. health care service NOT in manila
A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase III study to investigate the efficacy and safety of secukinumab (Cosentyx®) 300 mg administered subcutaneously in patients with active peripheral spondyloarthritis (pSpA)
With active peripheral spondyloarthritis (pSpA)
TH HBV ASO-001
chronic Hepatitis B (CHB)
EVALUATION OF Senna (Cassia) alata (Linn) Roxb. LEAF TOPICAL SOLUTION VERSUS KETOCONAZOLE 2% AS TREATMENT FOR SCALP SEBORRHEIC DERMATITIS
A randomized control trial aimed to determine the efficacy of cassia alata topica solution compared to ketoconazole 2% shampoo for the treatment of scalp seborrheic dermatitis
Scalp seborrheic Dermatitis
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
A global, randomized phase III study to evaluate perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin with radical cystectomy + pelvic lymph node dissection (RC+PLND) versus RC+PLND alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
Urinary Bladder Cancer, Muscle-invasive
EFFECTIVENESS AND SAFETY OF SOYBEAN 4% OINTMENT VERSUS CLOBETASOL PROPIONATE 0.05% OINTMENT IN MILD PLAQUE PSORIASIS (BSA <3%): A RANDOMIZED CLINICAL TRIAL
A randomized, double-blind clinical trrial on the efficacy and safety of soybean 4% ointment versus clobetasol propionate 0.05% ointment in mild plaque psoriasis (BSA <3%) at the Southern Philippines Medical Center.
Clinical remission using the PASI 90 response or ≥ 90% improvement in Psoriasis Area and Severity Index
Mild plaque psoriasis (BSA <3%)
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Inducible Urticaria (CINDU) in adolescents and adults inadequately controlled with H1-antihistamines
This is a Phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study. There is a screening period of up to 28 days, a 24 week double-blind treatment period, and a 12 week post-treatment follow-up period.
Chronic Inducible Urticaria (CINDU)
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
This study is a Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study, and aim to to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy in treating of Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Intranasal INNA-051 for Prevention of COVID-19 in Adults Following Close Contact With Individuals With SARS-CoV-2 Infection
A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Sustained Virologic Response in Chronic Hepatitis B Participants With and Without Nucleos(t)ide Therapy Who Have Received and Responded to GSK3228836 in a Previous Treatment Study
Chronic Hepatitis B Participants
A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease
The primary objective of this study is to demonstrate the superiority of inclisiran compared to placebo in reducing the risk of 3P-MACE (composite of CV death, non-fatal MI and non-fatal ischemic stroke) in participants with established ASCVD and a LDL-C ≥1.8 mmol/L(70 mg/dL)